Floatz logo

Vinorelbine

Endometrial Carcinoma

National Cancer Institute (NCI)Phase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

29 Active assets in the Endometrial Carcinoma cohort.

Asset / SponsorPhaseRating
Dasatinib
National Cancer Institute (NCI)
Phase 2CCC
GSK-2636771
National Cancer Institute (NCI)
Phase 2CCC
Crizotinib
National Cancer Institute (NCI)
Phase 2CCC
Dabrafenib
National Cancer Institute (NCI)
Phase 2CCC
Trastuzumab Emtansine
National Cancer Institute (NCI)
Phase 2CCC

View all 41 →

Same molecule, other indications

Vinorelbine is also rated in:

HER2 positive breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Recurrent Breast CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →